Core Insights - Trevi Therapeutics is advancing its investigational therapy Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) [1][4][5] Company Updates - The company has scheduled an End-of-Phase 2 meeting with the FDA in the first quarter of 2026 to discuss the clinical development and regulatory pathway for Haduvio [1][7] - A Phase 2b trial for RCC is planned to initiate in the first half of 2026 [1][7] - David Hastings, the new Chief Financial Officer, will attend the LifeSci Partners Corporate Access Event alongside senior management [7] Product Information - Haduvio (oral nalbuphine ER) is the first investigational therapy to show a statistically significant reduction in cough frequency in clinical trials for both IPF chronic cough and RCC [4] - The therapy acts on the cough reflex arc as a kappa agonist and mu antagonist, targeting opioid receptors involved in chronic cough control [4] Market Need - There are approximately 150,000 U.S. patients with IPF, with two-thirds experiencing uncontrolled chronic cough [5] - About 228,000 U.S. patients have non-IPF ILD, with 50-60% suffering from uncontrolled chronic cough [5] - RCC affects an estimated 2-3 million U.S. patients and is characterized by a persistent cough lasting over 8 weeks despite treatment for underlying conditions [6]

Controlling cough where it countsTM Positive Topline Results from Phase 2b Trial of Haduvio in Patients with IPF Chronic Cough (CORAL) June 2, 2025 Nasdaq: TRVI Forward Looking Statement Disclaimer Statements contained in this presentation and oral statements made regarding the subject of this presentation regarding matters that are not historical facts are "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncer ...